Viral vector Manufacturing is a process started with the generation of cell lines and transfer of these cells with plasmids for the production of a viral vector, which are used to transduce patient T cells, before reintroducing into the patient. The global viral vector manufacturing market is valued at $393.40 Million in 2019 and is estimated to reach $1,214.2 Million by 2025, at a CAGR of 22.6% during the forecast period. Factors such as rising prevalence of genetic disorders, cancer, and infectious diseases, the effectiveness of viral vectors, and ongoing research into viral vector-based gene and cell therapies are driving the market growth. The significant restraints hampering the market growth are high costs of gene therapy, the risk of mutagenesis, and short shelf life of viral vectors. Technological advancements are creating profitable opportunities for the market growth during the forecast period.
Research Study Objectives:
- Define, estimate, and forecast the Viral Vector Manufacturing market statistics by type, disease, application, end user, and regions concerning the individual growth drivers, market trends and their contribution toward the Viral Vector Manufacturing market growth
- Provides comprehensive information regarding the key factors influencing the market growth (Drivers, Restraints & Challenges, and Opportunities)
- Estimate & forecast the market size of all the segments concerning geographies including North America, Europe, Asia Pacific (APAC), South America and the Middle East and Africa (MEA).
- Recent competitive developments including M&A (Mergers and Acquisitions), Partnerships, and Product Innovations are provided in the Viral Vector Manufacturing Market Analysis
- Analysis and conclusions on the future Viral Vector Manufacturing market outlook.
Top-down and bottom-up approaches are used to validate the Viral Vector Manufacturing Market Size and are used to estimate the size of other dependent submarkets. Key players in
the market are identified through various secondary sources; databases including Bloomberg Businessweek, Hoovers, Factiva, journals and associations and the market revenues are estimated and are thoroughly validated through primary and secondary research. Secondary research involves the study of annual and financial reports of top players in the market, whereas primary research includes extensive interviews with the KoL’s such as CEOs, directors, board members, VP’s, sales managers, engineers, marketing executives, technicians, account managers, investors, strategic decision makers and others. The
Viral Vector Manufacturing Market shares and breakdowns are determined using secondary sources and are verified by the primary sources. All possible parameters/factors that are affecting the
Viral Vector Manufacturing market demand are covered in the research study are verified through primary research, analysed and interpreted to get the final qualitative and quantitative data. This data is collected and added with detailed analysis from Envision Inteligence and presented in this report.
The scope of the Report
The Viral Vector Manufacturing market segmentation is as follows:
By Type
- Retroviral Vectors
- Lentiviral Vectors
- Gamma-Retroviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral Vectors
- Others
By Disease
- Cancer
- Genetic Disorders
- Infectious Disorders
- Others
By Application
By End Users
- Pharmaceutical & Biotechnology Companies
- Research Institutes
Geographical Analysis:
Viral Vector Manufacturing Market is segmented by geography into North America, South America, Europe, APAC and Middle East & Africa. U.S., Canada, Mexico and Costa Rica are analysed under North American region which is usually turning as the hotspot in the market. The South American region is further segregated into Brazil, Argentina, Chile, Columbia and some other emerging economies. In Europe, the market is extensively examined by covering U.K., Germany, France, Italy, Spain, Netherlands, Poland, Switzerland and some other promising economies. APAC is further categorised by countries into China, India, Japan, South Korea, Australia & New Zealand, Malaysia,
Singapore and many other emerging nations. In the Middle East & African region, Saudi Arabia, UAE, Iran, Iraq, Qatar, South Africa, Algeria, Morocco, Nigeria and so on countries are evaluated to understand the market growth lucidly.
Customization Options:
With the given research report, Envision Inteligence offers customisations as per the client’s specific requirements. The following customisation options offered for the Viral Vector Manufacturing Market include:
- Scope Revision
- Geographic Analysis
- Company Profiles
- Historical Data & Forecasting
- Key Contact Persons in companies
Global Viral Vector Manufacturing Market Research Report Includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have a complete market analysis through industry value chain analysis, Porter’s Five Force Model, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact on altering market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the significant Viral Vector Manufacturing market players, such as
- Kaneka Eurogentec S.A.
- FinVector Vision Therapies
- Brammer Bio LLC
- Oxford BioMedica
- Merck KGaA
- Along with these companies, many other companies are considered in the report while analysing the Global Viral Vector Manufacturing competitive strategies and environment. These companies held substantial share-owning to the nature of the industry whereas, the rest of the market shares are marginal chunks to regional and local level manufacturers. Other players also have considerable presence owing to its robust brand image, geographical reach and stable customer base.
